Pancreatic Acinar Cell Carcinoma Completed Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0040329 (Pancreatic Acinar Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01658943Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyTreatment